# Advisor Review - GPT-5-mini

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-11T13:50:45.157681
**Route:** OpenRouter + LaTeX
**Tokens:** 18039 in / 2557 out
**Response SHA256:** def734f05aaae690

---

FINDINGS SUMMARY (focusing only on the required “fatal error” checks)

I found fatal errors that must be corrected before submission. They fall under Data-Design Alignment and Internal Consistency. There are no fatal Regression Sanity or Completeness problems in the tables and reported regression outputs (standard errors, coefficients, R², N, etc. appear numerically plausible and present).

List of fatal errors (each with location, error, and fix):

FATAL ERROR 1: Data-Design Alignment — Treatment timing textual/listing mismatch
  Location: Introduction and Section 2.1 (paragraphs describing the first cohort), and Figure/paragraph in Results ("The first eight states enacted laws effective in 2021Q3 ...").
  Error: The text repeatedly states that the first cohort comprised eight states treated in 2021Q3 (and specifically lists Idaho, Oklahoma, Tennessee, Iowa, South Carolina, North Dakota, Texas, and Arizona as 2021Q3). The treatment coding table (Table "Treatment Laws", and the Data Appendix cohort breakdown) shows a different assignment: Idaho, Oklahoma, Tennessee, Iowa, and South Carolina are 2021Q3 (5 states); North Dakota, Texas, and Arizona are assigned to 2021Q4 in the table. Thus the textual description of cohort membership/timing contradicts the treatment-coding table.
  Why fatal: This is a core data-design alignment problem. The credibility of a staggered DiD analysis depends on correct and consistent coding of treatment timing across text, tables, figures, and estimation code. If readers (and reviewers) cannot reconcile the listed treatment dates with the dates actually used in estimation, the design is unclear and the results could be incorrect or irreproducible.
  Fix:
    - Reconcile and make consistent the authoritative treatment coding. Decide whether Texas, North Dakota, and Arizona are 2021Q3 or 2021Q4 (based on your pre-specified rule: first full quarter after effective date, with <=15 days assigned to that quarter). Then:
      - Update the treatment-coding Table (tab:treatment_laws) if it is wrong, or update all textual references (Introduction, Background, Results, figure captions, and any mentions in the Appendix) to match the table and the estimation code.
      - Update the "first cohort" description and the list of states in all places to match the final coding.
      - Re-run all estimations if the treatment dates used in the code differ from the table; report the estimator results corresponding to the final, internally consistent treatment-coding.
    - Add a short footnote/appendix line clarifying the tie-breaking rule and showing the mapping from statutory effective date → assigned treatment quarter for the disputed states (with date math), so a reader can verify the cohort assignment.

FATAL ERROR 2: Internal Consistency — Incorrect statement about number of post-treatment quarters for earliest cohort (numerical inconsistency)
  Location: Introduction and Results (several places). Quoted: "up to fourteen post-treatment quarters" for the earliest 2021Q3 cohort; elsewhere event-study axis discusses up to 14 quarters.
  Error: With sample coverage through 2024Q4, a treatment that begins in 2021Q3 provides at most 13 post-treatment quarters (2021Q4 through 2024Q4 inclusive is 12, but if counting 2021Q3 as first post-treatment quarter, the maximum is 13 — in any case, 14 is not attainable). The manuscript states "up to fourteen post-treatment quarters" which is arithmetically incorrect given 2015Q1–2024Q4 data and 2021Q3 earliest treatment.
  Why fatal: This is a numeric inconsistency about the design/data coverage and can mislead readers about how much post-treatment variation exists for event-study identification and power. It undermines claims about statistical power and the length of the dynamic window.
  Fix:
    - Correct the numeric statement to the true maximum number of post-treatment quarters for the earliest cohort, and ensure all places that mention the same number (Introduction, Data section, Results/Event study captions, Appendix where cohorts are summarized) are updated.
    - Recompute and report the exact number of post-treatment quarters used in the event-study per cohort (e.g., "earliest 2021Q3 cohort contributes up to 13 post-treatment quarters; later cohorts contribute fewer"), and update any text that uses the incorrect figure when arguing about power or event-study length.
    - If any figures/axis labels or event-study binning assumed 14 quarters, regenerate those figures/tables after correcting binning.

FATAL ERROR 3: Internal Consistency — Ambiguous counting of DC / control group wording
  Location: Introduction and Data sections. Examples: "all fifty states and the District of Columbia" / "twenty-eight states (plus DC) serve as never-treated controls" / later in tables "Never-treated states = 28".
  Error: The prose is inconsistent/ambiguous about whether DC is included among the 28 never-treated controls or counted separately. At places it says "twenty-eight states (plus DC)" which suggests 29 control units, but elsewhere N treated = 23 and never-treated = 28 (23+28=51), consistent with DC being included in the 28. The phrasing is confusing.
  Why fatal: Counting the number of cross-sectional units is fundamental to cluster inference and replication. Ambiguous language about whether DC is included can create confusion about the sample size (51 vs 52) and clustering.
  Fix:
    - Make the language precise and consistent: state explicitly "51 state-equivalents (50 states plus DC)" and then "23 treated state-equivalents and 28 never-treated state-equivalents (this count includes DC among the never-treated, if applicable)" OR if DC is excluded/treated, correct all occurrences.
    - Ensure the N reported in tables (N, number of clusters) matches this clarified description.
    - If DC was omitted by mistake from estimation or the treatment list, clarify and re-run analyses as needed.

Notes on scope: I did not find numerical regression outputs that violate the Regression Sanity rules you specified (no absurd SEs, coefficients, negative SEs, NA/NaN in tables, or R² outside [0,1]). I did not find placeholders like "TBD" or "NA" in tables. Reported sample sizes, SEs, and results are present.

However, the three fatal errors above relate to the core data-design and internal consistency requirements of a staggered DiD paper and must be fixed before sending to referees. In particular, Error 1 (mismatch between textual cohort claims and the treatment-coding table / Appendix) is the most serious: it directly undermines reproducibility and the reader's ability to verify that the treated cohorts used in estimation match the described policy timing.

ADVISOR VERDICT: FAIL